The Quantum‐R study was a global phase 3 study comparing quizartinib vs investigator's choice of salvage chemotherapy in patients aged ≥18 years with ECOG PS ≤2 and relapsed/refractory FLT3‐ITD primary AML with or without HCT.60 The gene discussed is FLT3; the disease is acute myeloid leukemia.